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FlutemetamolAside from apolipoprotein E (APOE), genetic risk factors for β amyloid deposition in cognitively intact indi-
viduals remain to be identiﬁed. Brain derived neurotrophic factor (BDNF) modulates neural plasticity,
which has been implicated in Alzheimer's disease. We examined in cognitively normal older adults whether
the BDNF codon 66 polymorphism affects β amyloid burden and the relationship between β amyloid burden
and cognitive scores, and how this relates to the effect of APOE. Amyloid load was measured by means of
18F-ﬂutemetamol PET in 64 community-recruited cognitively intact individuals (mean age 66, S.D. 5.1).
Recruitment was stratiﬁed according to a factorial design with APOE (ε4 allele present vs absent) and
BDNF (met allele at codon 66 present vs absent) as factors. Individuals in the four resulting cells were
matched by the number of cases, age, and gender. Among the APOE ε4 carriers, BDNF met positive subjects
had a signiﬁcantly higher amyloid load than BDNF met negative subjects, while BDNF met carrier status did
not have an effect in APOE ε4 noncarriers. This interaction effect was localized to precuneus, orbitofrontal
cortex, gyrus rectus, and lateral prefrontal cortex. In the APOE ε4/BDNF met carriers, a signiﬁcant inverse
relationship existed between episodic memory scores and amyloid burden but not in any of the other groups.
This hypothesis-generating experiment highlights a potential role of BDNF polymorphisms in the preclinical
phase of β amyloid deposition and also suggests that BDNF codon 66 polymorphisms may inﬂuence resilience
against β amyloid-related effects on cognition.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.ctor; APOE, apolipoprotein E;
R in composite cortical volume
sonance imaging; PET, positron
heimer's disease; PVC, partial
University Hospitals Leuven,
l.: +32 16344280; fax: +32
e (R. Vandenberghe).
nc.Open access under CC BY-NC-SA lic1. Introduction
In a variable proportion of cognitively intact older subjects, in vivo
amyloid imaging has revealed increased cerebral Aβ deposition,
sometimes to a degree identical to that seen in patients with clinically
probable Alzheimer's disease (AD) (Aizenstein et al., 2008; Mintun
et al., 2006; Morris et al., 2010; Nelissen et al., 2007; Pike et al.,
2007; Rowe et al., 2007, 2010). This ﬁnding has attracted a lot of
interest as itmay be a possiblemarker for preclinical Alzheimer's disease
(Sperling et al., 2011). The only risk factor proven to be associated with
increased amyloid load in a cognitively intact population is the apolipo-
protein E (APOE) ε4 allele (Fleisher et al., 2013; Morris et al., 2010;
Reiman et al., 2009; Vemuri et al., 2010; Villemagne et al., 2011),ense.
Table 1
Demographic and neuropsychological characteristics of subjects in the original dataset.
Values represent means and standard deviations (in parenthesis) unless stated other-
wise; gender is expressed in number of individuals. Abbreviations:M = male; F = female;
MMSE = Mini Mental State Examination; CDR = Clinical Dementia Rating global score;
AVLT = Rey Auditory Verbal Learning Test; DR = delayed recall; TL = total learning;
TMT = Trail Making Test part B divided by part A; BNT = Boston Naming Test; AVF =
Animal Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM = Raven's Progressive
Matrices; +ve = positive; -ve = negative.
Demographic data and neuropsychological test scores in the original dataset
Genetic groups P
BDNF
met +ve
BDNF
met −ve
BDNF
met +ve
BDNF
met −ve
APOE
ε4 +ve
APOE
ε4 +ve
APOE
ε4 −ve
APOE
ε4 −ve
Gender (M/F) 7/9 9/6 8/8 10/7 0.8
Age 65.4 (5.5) 66.5 (4.3) 65.3 (5.5) 65.8 (5.4) 0.9
Education
(years)
13.3 (3.0) 12.5 (2.2) 13.9 (2.2) 14.7 (3.6) 0.2
Handedness 95.0 (14.5) 100.0 (0.0) 96.7 (7.7) 100.0 (0.0) 0.2
MMSE (/30) 29.0 (0.9) 28.7 (1.1) 29.3 (0.6) 28.9 (0.9) 0.3
AVLT DR (/15) 11.4 (2.4) 10.3 (3.6) 11.3 (2.8) 10.6 (2.2) 0.6
AVLT TL (/75) 48.9 (7.8) 50.1 (8.6) 51.1 (12.3) 49.0 (9.1) 0.9
BNT (/60) 53.1 (5.4) 51.9 (6.5) 52.6 (4.8) 54.2 (3.2) 0.6
AVF 18.6 (4.7) 19.9 (5.3) 21.8 (5.5) 21.2 (4.2) 0.3
LVF 33.5 (11.8) 31.1 (8.1) 33.6 (9.9) 37.4 (9.8) 0.4
RPM 39 (8.6) 42.1 (9.2) 44.3 (7.3) 46.5 (7.5) 0.07
TMT B/A 2.9 (1.0) 2.5 (0.6) 2.6 (1.0) 2.5 (1.1) 0.5
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1993; Rebeck et al., 1993). Beyond what can be explained by APOE
alone, a family history of AD is associated with increased brain amyloid
levels in cognitively intact older adults (Xiong et al., 2011). According to
a recent study, polymorphisms of complement component (3b/4b)
receptor-1 (CR1)modulate the effect of APOE ε4 on brain amyloid levels
(Thambisetty et al., 2012). These ﬁndings suggest a complex interaction
between genetic variants and brain amyloid deposition in preclinical
AD (Sperling et al., 2011).
A failure of neural plasticity has been put forward as a unifying
theme spanning across the multiple pathways that lead to clinical
AD (Arendt, 2001; Ashford and Jarvik, 1985; Mesulam, 1999, 2000;
Teter, 2004). Brain derived neurotrophic factor (BDNF), a neurotro-
phin with high afﬁnity for tyrosine kinase B receptors (TrkB), has
been implicated in neural plasticity (Gorski et al., 2003; Webster et al.,
2006) as well as in memory, both in humans (Erickson et al., 2011)
and in animal models (Li et al., 2008; Okuno et al., 1999; Osada et al.,
2008). In humans, a common single nucleotide polymorphism (SNP)
in the 5′ prodomain of the BDNF gene which results in valine to methi-
onine substitution at codon 66 (val66met), affects memory function
(Chen et al., 2004; Dennis et al., 2011; Egan et al., 2003; Hariri et al.,
2003; McAllister et al., 2012; Miyajima et al., 2008; Voineskos et al.,
2011), hippocampal volume and fMRI responses (Egan et al., 2003;
Pezawas et al., 2004). The met allele occurs in approximately 35% of
the Caucasian population (Cheeran et al., 2008). Given the prominent
role of BDNF in neuroplasticity and a failure of neural plasticity as a
potential common theme in AD (Mesulam, 1999), the BDNF-TrkB path-
way could theoretically be linked to a host of AD-related processes at
the molecular, neuronal or systems level.
The original hypothesis underlying the design of our study was
that BDNF polymorphisms might inﬂuence the resilience against
β amyloid related changes (Nelissen et al., 2007). We hypothesized
that BDNF val carriers would be able to compensate for the presence
of β amyloid in a better way than met carriers. Such resilience might
be manifest as a difference between genetic strata in how Aβ load
affects cognitive scores and also as a difference in compensatory
mechanisms at the brain systems level (Nelissen et al., 2007). As a
ﬁrst step, we examined whether there were any direct effects of the
BDNF codon 66 polymorphism on amyloid retention in cognitively
intact older adults, measured by means of 18F-ﬂutemetamol positron
emission tomography (PET) (Koole et al., 2009; Nelissen et al., 2009;
Vandenberghe et al., 2010, 2013).
2. Subjects and methods
2.1. Subjects
The main cohort consisted of 64 community-recruited older adults
between 50 and 75 years of age (mean age = 66, S.D. = 5.1, range
53–74) (Table 1). The study exclusion criteria were a Mini Mental
State Examination (Folstein et al., 1975) score lower than 27, a
Clinical Dementia Rating score (Morris et al., 1997) higher than 0, sig-
niﬁcant neurological or psychiatric history, signiﬁcant brain lesions
on structural MRI, and below-normal test scores on conventional
neuropsychological assessment (Table 1). Inclusion was stratiﬁed
per age bin (50–59, 60–64, 65–69, 70–75) for two genetic factors:
BDNF (met allele present or absent) and APOE (ε4 allele present or
absent). The cells of this 2 × 2 factorial design were prospectively
matched for number of cases, gender, age, education and handedness
(Edinburgh Handedness Inventory) (Table 1). BDNF and APOE vari-
ants were genotyped by sequencing at the Genetic Service Facility
(GSF, www.vibgeneticservicefacility.be) of the VIB Department of
Molecular Genetics.
The genetic distribution among all subjects who underwent
screening, was 10% BDNF met positive (+ve)/APOE ε4 +ve, 16% BDNF
met negative (–ve)/APOE ε4 +ve, 33% BDNF met +ve/APOE ε4 −ve,and 41% BDNF met −ve/APOE ε4 −ve. After genetic stratiﬁcation, the
genetic distribution of the ﬁnal cohort (n = 64) was as follows: 25%
were BDNF met +ve/APOE ε4 +ve, 23% BDNF met−ve/APOE ε4 +ve,
25% BDNF met +ve/APOE ε4−ve, and 27% were BDNF met−ve/APOE
ε4−ve.
The protocol was approved by the Ethics Committee University
Hospitals Leuven (EudraCT: 2009-014475-45) and written informed
consent was obtained from all subjects in accordance with the
Declaration of Helsinki.
2.2. Image acquisition
18F-ﬂutemetamol PET imaging was performed at the University
Hospitals Leuven. The acquisition procedure has been described before
(Koole et al., 2009; Nelissen et al., 2009; Vandenberghe et al., 2010,
2013). Images were acquired on a 16-slice Siemens Biograph PET/CT
scanner (Siemens, Erlangen, Germany). The PET tracer was injected
intravenously as a bolus (mean activity 150.6 MBq, S.D. 8 MBq, range
137.9–192.5 MBq) in an antecubital vein. Image acquisition started
90 min after tracer injection and lasted for 30 min. Prior to the PET
scan, a low-dose computed tomography (CT) scan was performed
for attenuation correction. Random and scatter corrections were also
applied. Images were reconstructed using Ordered Subsets Expectation
Maximization (OSEM; 4 iterations × 16 subsets).
A high-resolution T1-weighted structural MRI was obtained on
a 3 T Philips Intera system equipped with an 8-channel receive-only
head coil (Philips SENSitivity Encoding head coil), using a 3D
turbo ﬁeld echo sequence (coronal inversion recovery prepared 3D
gradient-echo images, inversion time 900 ms, TR = 9.6 ms, TE =
4.6 ms, ﬂip angle 8°, ﬁeld of view = 250 × 250 mm, 182 slices; voxel
size 0.98 × 0.98 × 1.2 mm3).
2.3. Image analysis
All analyses were performed using Statistical Parametric Mapping
8 (SPM8, http://www.ﬁl.ion.ucl.ac.uk/spm). The PET data were recon-
structed as 6 frames of 5 min and realigned to the ﬁrst frame to correct
for potential headmotion. Subsequently, the 6 frames were summed to
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image was then co-registered to his/her PET summed image. This
MR image was subsequently normalized to the SPM8 T1 template in
Montreal Neurological Institute (MNI) space using a uniﬁed segmenta-
tion approach. Next, this normalization matrix was applied to the
individual's co-registered PET summed image.
From the spatially normalized images (voxel size 2 × 2 × 2 mm3)
standardized uptake value ratios (SUVR) were calculated with cere-
bellar gray matter as reference region, resulting in SUVR images.
The cerebellar gray matter reference region was deﬁned as areas 91
to 108 of the Automated Anatomical Labelling atlas (AAL) (Tzourio-
Mazoyer et al., 2002). The cerebellar reference region was resliced
to each individual's normalized PET summed image. In order to
exclude white matter (WM) content, it was masked by the normal-
ized and modulated subject-speciﬁc gray matter (GM) map, with
the threshold for masking set at 0.3.
We also deﬁned a composite cortical volume of interest. This was
composed of 5 bilateral cortical areas, i.e. frontal, parietal, anterior
cingulate, precuneus/posterior cingulate and lateral temporal deﬁned
as AAL areas 3–10, 13–16, 23–28, 31–32, 35–36, 57–70, 81–82, 85–90.
The composite cortical VOI was resliced to each individual's normal-
ized PET summed image. In order to exclude WM content, it was
masked by the normalized and modulated subject-speciﬁc GM map,
with the threshold for masking set at 0.3.
In one of the subjects the structural T1 image was missing due to a
contraindication for MRI. This individual's PET summed image was
normalized to the group mean normalized PET summed image creat-
ed from the 63 remaining subjects. The AAL-derived cerebellar and
composite cortical VOIs were co-registered to this normalized PET
summed image and were masked with the mean normalized modu-
lated GM map (thresholded at 0.3) created out of the 63 normalized
modulated GM maps. This individual's SUVR image was calculated
based on this normalized PET summed image with the cerebellar
gray matter reference region.
As a secondary measure we also worked on partial volume
corrected (PVC) data. PVC was based on the MRI using the modiﬁed
Müller-Gärtner method (Müller-Gärtner et al., 1992). This method
determines tracer concentration per unit volume of GM. In the mod-
iﬁed method, we use probabilistic segmentation instead of binary
maps. The normalized unmodulated GM and WM segmentations
were used to estimate different tissue fractions per voxel. PVC
was applied to the normalized PET summed images. The remaining
procedures were identical to those outlined above.
We also tested for any group differences in tracer retention in the
cerebellar reference region, as this could cause spurious differences in
cortical SUVR values. We calculated the standardized uptake values
(SUV) in the cerebellar gray matter region. SUV values were deﬁned
as the ratio of mean activity concentration in cerebellar gray matter
in the normalized PET summed image [MBq] to the injected activity
concentration [MBq/kg] per total body weight [kg].
2.3.1. Statistical analysis
We statistically analyzed all SUVR images using two approaches:
one was based on the global composite cortical VOI, the other was
voxel-based. In the global composite cortical analysis our primary
outcome measure was mean SUVR value calculated in the composite
cortical VOI (SUVRcomp). We used SUVRcomp as the dependent variable
and performed a factorial ANOVA with BDNF (2 levels: met allele
present vs absent) and APOE (2 levels: ε4 allele present vs absent)
as between-subjects factors. In addition, we performed a conﬁrmatory
non-parametric Kruskal–Wallis ANOVA on the 4 genetic groups with
SUVRcomp as the dependent variable.
In the voxel based analysis, using SPM8, we analyzed SUVR images
bymeans of a factorial ANOVAwith BDNF (2 levels:met allele present vs
absent) and APOE (2 levels: ε4 allele present vs absent) as between-
subjects factors. The signiﬁcance threshold was set at a cluster-levelof P b 0.05 family-wise error (FWE) corrected for the entire brain search
volume, with the voxel-level threshold set at uncorrected P b 0.001.
The partial-volume corrected data were analyzed using a factorial
ANOVA with BDNF (2 levels: met allele present vs absent) and APOE
(2 levels: ε4 allele present vs absent) as between-subjects factors.
Differences in the SUV values in the cerebellar gray matter VOI
were analyzed by a factorial ANOVA with 2 between-subjects factors:
BDNF (2 levels: met allele present vs absent) and APOE (2 levels: ε4
allele present vs absent).
2.4. Relationship to episodic memory test scores
To assess the relationship between 18F-ﬂutemetamol retention
and episodic memory measures, we conducted a linear regression
analysis with either AVLT delayed recall score (DR) or total learning
score (TL) as dependent variable and SUVRcomp as independent
variable. This analysis was performed across the entire group as well
as within each genetic group separately. To evaluate whether the rela-
tionship was speciﬁcally observed with episodic memory scores, we
also performed a linear regression analysis with other tests from our
cognitive battery: Boston Naming Test (BNT), Animal Verbal Fluency
Test (AVF) and total score on Raven's Progressive Matrices (RPM).
3. Results
The four genetic groups did not differ in age, gender, years of
education or neuropsychological test scores (Table 1).
3.1. Effect of APOE and BDNF polymorphisms on SUVR
3.1.1. Global composite cortical analysis
Our primary outcome measure, SUVRcomp, differed signiﬁcantly
between the four genetic groups (F(3,60) = 5.37, P = 0.002) (Fig. 1).
The main effect of APOE was signiﬁcant: APOE ε4 carriers had signiﬁ-
cantly higher ligand retention than APOE ε4 noncarriers (F(1,60) =
7.14, P = 0.01). The main effect of BDNF genotype was not signiﬁcant
(F(1,60) = 1.02, P = 0.32). The interaction between BDNF and
APOE on ligand retention was signiﬁcant (F(1,60) = 7.94, P =
0.007): BDNF met +ve/APOE ε4 +ve carriers had signiﬁcantly
higher ligand retention (mean SUVRcomp = 1.37, S.D. = 0.21) than
BDNF met −ve/APOE ε4 +ve carriers (mean SUVRcomp = 1.23,
S.D. = 0.12) (P = 0.01), while amyloid ligand retention in APOE ε4
noncarriers did not differ between BDNF met +ve (mean SUVRcomp =
1.17, S.D. = 0.06) and BDNF met −ve cases (mean SUVRcomp = 1.24,
S.D. = 0.11) (P = 0.2) (Fig. 2A and B).
Non-parametric analysis conﬁrmed these results. The four genetic
groups differed signiﬁcantly in SUVRcomp (H(df 3, N 64) = 11.35,
P = 0.01). The main effect of APOE was signiﬁcant: APOE ε4 carriers
had signiﬁcantly higher ligand retention than APOE ε4 noncarriers
(H(df 1, N 64) = 5.25, P = 0.02). The main effect of BDNF genotype
was not signiﬁcant (H(df 1, N 64) = 0.04, P = 0.85). Planned
comparisons revealed that BDNF met +ve/APOE ε4 +ve carriers
exhibited higher ligand retention (mean rank = 19.1) than BDNF
met −ve/APOE ε4 +ve carriers (mean rank = 12.6) (P = 0.048).
Amyloid ligand retention tended to be lower in BDNF met+ve (mean
rank = 13.8) than in BDNF met −ve (mean rank = 19.9) APOE ε4
noncarriers (P = 0.07).
Analysis of partial volume corrected data conﬁrmed these results. PVC
SUVRcomp was signiﬁcantly different between the four genetic groups
(F(3,59) = 4.64, P = 0.006). The main effect of APOE was signiﬁcant:
APOE ε4 carriers had signiﬁcantly higher ligand retention than APOE ε4
noncarriers (F(1,59) = 6.96, P = 0.01). The main effect of BDNF geno-
type was not signiﬁcant (F(1,59) = 0.55, P = 0.46). The interaction be-
tween BDNF and APOE on ligand retention was signiﬁcant (F(1,59) =
6.7, P = 0.01): BDNF met +ve/APOE ε4 +ve carriers had signiﬁcantly
higher ligand retention (mean SUVRcomp = 1.56, S.D. = 0.39) than
Fig. 1. Distribution of 18F-ﬂutemetamol retention levels for the different genetic groups. X axis: age in years; Y axis: SUVRcomp.
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0.24) (P = 0.02), while amyloid ligand retention in APOE ε4 noncarriers
did not differ between BDNF met +ve (mean SUVRcomp = 1.24, S.D. =
0.09) and BDNF met −ve cases (mean SUVRcomp = 1.35, S.D. = 0.18)
(P = 0.19).
SUV values in cerebellar gray matter did not differ between genetic
groups (F(3,60) = 0.54, P = 0.66): There was no difference between
APOE ε4 carriers and noncarriers (F(1,60) = 0.21, P = 0.65), between
BDNF met carriers and noncarriers (F(1,60) = 0.55, P = 0.46) and
neither was there any interaction (F(1,60) = 0.79, P = 0.38).
3.1.2. Voxel-based analysis
The whole-brain voxel-wise analysis conﬁrmed the ﬁndings from
the composite cortical analysis. There was a signiﬁcant main effect of
APOE: APOE ε4 carriers had signiﬁcantly higher 18F-ﬂutemetamol
retention than APOE ε4 noncarriers in the posterior cingulate (clusterFig. 2. Effects of BDNF andAPOE genotypes on amyloid depositionmeasured by SUVRcomp.
(A) SUVRcomp in the different genetic subgroups. (B) Further differentiation depending
on APOE and BDNF subgroups.peak−14,−20, 40, Z = 4.26, extent of voxels (ext.) 178 mm3, corr.
cluster-level P = 0.025) (Fig. 3A). There was no main effect of BDNF
genotype (corr. cluster-level P > 0.7). The interaction effect of
APOE and BDNF was signiﬁcant in precuneus (cluster peak 10, −40,
42, Z = 4.71, ext. 437 mm3, corr. cluster-level P = 0.0001), left
orbitofrontal cortex (cluster peak −8, 64, −14, Z = 4.69, ext.
387 mm3, corr. cluster-level P = 0.0003), right orbitofrontal cortex
(cluster peak 16, 68, −2, Z = 4.37, ext. 240 mm3, corr. cluster-level
P = 0.006), left gyrus rectus (cluster peak −8, 22, −18, Z = 4.62,
ext. 252 mm3, corr. cluster-level P = 0.004), right gyrus rectus (clus-
ter peak 16, 28, −28, Z = 4.35, ext. 209 mm3, corr. cluster-level
P = 0.012), right middle frontal gyrus (cluster peak 34, 46, 28, Z =
4.14, ext. 316 mm3, corr. cluster-level P = 0.001) and right inferior
frontal sulcus (cluster peak 50, 38, 6, Z = 3.88, ext. 281 mm3, corr.
cluster-level P = 0.002) (Fig. 3B). Simple effects revealed that BDNF
met +ve/APOE ε4 +ve carriers had higher ligand retention than
BDNF met −ve/APOE ε4 +ve carriers in posterior cingulate (cluster
peak at 2, −32, 42, Z = 4.25, ext. 388 mm3, corr. cluster-level
P = 0.0003), gyrus rectus (cluster peak at −4, 34, −26, Z = 4.44,
ext. 196 mm3, corr. cluster-level P = 0.016), insula (cluster peak at
36, 8, −12, Z = 4.89, ext. 311 mm3, corr. cluster-level P = 0.001)
and posterior middle temporal cortex (cluster peak at 62, −62, 4,
Z = 4.23, ext. 168 mm3, corr. cluster-level P = 0.03). There was no
difference between BDNF met +ve/APOE ε4 −ve carriers and BDNF
met−ve/APOE ε4−ve carriers (corr. cluster-level P > 0.9).
3.1.3. Relationship between β amyloid load and episodic memory
Across the entire sample, SUVRcomp did not correlate with AVLT
DR (P = 0.38) or TL (P = 0.16). When analyzed per genetic group,
a highly signiﬁcant and negative correlation was seen only in the
group of BDNF met +ve/APOE ε4 +ve carriers (DR: r = −0.62,
P = 0.01, and TL: r = −0.58, P = 0.02) (Fig. 4A and B, red lines).
In the other groups the correlation remained far below signiﬁcance
(P > 0.49) (Table 2). A formal pairwise comparison however of the re-
gression slopes between groups did not reach signiﬁcance (P > 0.05)
(Thöni, 1977).
None of the other cognitive test scores showed any correlation
with β amyloid when tested across the entire sample (P > 0.17) or
per group (Table 2).
4. Discussion
Our study revealed two key novel ﬁndings. First, APOE ε4 carriers
exhibited a higher β amyloid load in the presence of one or two BDNF
met alleles compared to BDNF met noncarriers (Figs. 1, 2). Second, an
Fig. 3. Statistical parametric map of the main effect of APOE (A) and the interaction effect between APOE and BDNF (B). (A) Main effect of APOE genotype: increased
18F-ﬂutemetamol retention in APOE ε4 +ve carriers compared to APOE ε4 −ve carriers in the posterior cingulate. (B) Interaction effect between BDNF and APOE: increased
18F-ﬂutemetamol retention in the precuneus, orbitofrontal cortex, gyrus rectus, middle frontal gyrus, and inferior frontal sulcus. Images are displayed at voxel-level P b 0.001,
only clusters that reached corrected cluster-level P b 0.05 are shown. SPM t maps are projected onto axial, sagittal, and coronal sections of the SPM8 standard single subject
T1 template and as SPM8 glass brain views.
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BDNF met/APOE ε4 carriers but not in any of the other subgroups.
The interaction effect between BDNF and APOE on β amyloid load
was unexpected and needs further conﬁrmation by independent
studies. The genetic stratiﬁcation for APOE and BDNF prior to recruit-
ment for scanning is a unique feature of our cohort that was probably
critical for obtaining this novel ﬁnding. In the group of individuals
volunteering for this study, after applying all non-genetic criteria for
in/exclusion, the proportion of BNDF met+ve/APOE ε4 +ve subjects
was only 10%. After stratiﬁcation this was raised to 25%. It is this
genetic combination that drives the interaction. Had we not strived
for a balanced factorial design with cells matched for numbers at
recruitment, the interaction effect would almost certainly have been
missed. This means that we had to genotype much higher numbers
of subjects than were actually able to enter the scanning phase of
the study. Replication of the interaction effect will probably also
have to be based on samples enriched for the naturally least frequent
combination of BNDF met and APOE ε4 carriers.
Most of the subjects with raised amyloid were APOE ε4 carriers
with BDNF met allele at codon 66 (Fig. 1). The number of subjects
with raised amyloid is relatively low but impacts relatively strongly
on the statistical outcome. Non-parametric testing conﬁrmed that
BDNF met carriage affected Aβ load. Our ﬁndings were obtained in
a cohort stratiﬁed at recruitment for APOE and BDNF polymor-
phisms according to a balanced factorial design with demographically
matched subjects. The stratiﬁcation, the balanced design and the fact
that we only tested these two gene polymorphisms, reduces the risk
of a false-positive. As a relatively low number of the 64 healthy sub-
jects had a raised Aβ load, the power of our study to determine an
inﬂuence of genetics is limited and any negative ﬁndings should be
interpreted with caution. The proportion of subjects with raised
amyloid increases with age (Morris et al., 2010). Further studies in a
higher age range will be needed to conﬁrm whether the interaction
is present also in an older population.
We used the volumetric MRI scan for normalization and the
segmented graymattermaps for deﬁnition of the cerebellar graymatter
and the composite cortical volume. The method we applied differs
from the purely PET-based method applied in the phase 2 study of
18F-ﬂutemetamol (Vandenberghe et al., 2010). As a consequence, wecannot simply use the cut-off from the phase 2 study to discriminate
positive from negative cases in a binary manner. Furthermore, in a
cognitively intact population of older adults, a signiﬁcant minority
exhibits intermediary values.While categorical discrimination between
positive and negative individuals is relevant for clinical purposes, a
binary division in positive and negative cases is not essential for the
current scientiﬁc question.
The interaction effect was seen in frontobasal cortex, precuneus,
and lateral prefrontal cortex, which are well-established areas of pre-
dilection for amyloid deposition in the initial phase of the disease
(Aizenstein et al., 2008; Fleisher et al., 2011, 2013; Mintun et al.,
2006; Pike et al., 2007; Rowe et al., 2007). For posterior cingulate
and precuneus this has been linked to their status as a network hub
(Buckner et al., 2009; Mormino et al., 2011), including their centrality
in the connections from the hippocampal formation to parietal cortex
(Mesulam et al., 1977; Seltzer and Pandya, 1994). Why orbitofrontal
cortex regularly recurs as an area of predilection, is less clear. In any
case, numerous studies of the earliest changes in amyloid load in AD
have reported increased amyloid load in this region (Braak and Braak,
1991; Chételat et al., 2010, 2011; Fleisher et al., 2011, 2013). Orbitofrontal
cortex also shows hypometabolism on 18F-deoxyglucose PET early in the
AD disease course (Herholz et al., 2002).
The original purpose of our factorial design was to evaluate the
effect of BDNF on functional reorganization and plasticity (Nelissen
et al., 2007) in response to β amyloid related injury. We predicted
that compared to BDNF met carriers BDNF val status would confer a
higher compensatory capacity for functional reorganization in the
face of increased Aβ amyloid (Nelissen et al., 2007). Given ample
evidence for a relationship between BDNF polymorphism and episodic
memory (Chen et al., 2004; Dennis et al., 2011; Egan et al., 2003;
Hariri et al., 2003; McAllister et al., 2012; Miyajima et al., 2008;
Voineskos et al., 2011) and given the prominent role of episodic mem-
ory decline in the earliest clinical stages of Alzheimer's disease, we
primarily evaluated whether BDNF affected the relationship between
Aβ deposition and episodicmemory.We found a strong negative corre-
lation betweenAβ deposition and episodicmemory encoding and recall
in the BDNFmet+ve/APOE ε4 +ve carriers but not in any of the three
other groups (Fig. 4, Table 2). This ﬁnding is in line with our a priori
hypothesis that BDNF polymorphism may inﬂuence resilience against
Fig. 4. Correlation between amyloid ligand retention and AVLT delayed recall (DR) and total learning (TL) scores. (A) Negative correlation between SUVRcomp values and AVLT DR
scores in the BDNF met +ve/APOE ε4 +ve group (red line). (B) Negative correlation between SUVRcomp values and AVLT TL scores in the BDNF met +ve/APOE ε4 +ve (red line).
SUVRcomp (Y axis) plotted by AVLT DR or TL scores (X axis): BDNFmet+ve/APOE ε4 +ve (red triangles), BDNFmet−ve/APOE ε4 +ve (blue squares), BDNFmet+ve/APOE ε4−ve
(red circles) and BDNF met −ve/APOE ε4 −ve (blue diamonds). When the correlation does not reach signiﬁcance, no regression line is shown.
Table 2
Linear regression analysis between SUVRcomp and cognitive test scores in each of the
four genetic groups. Values represent correlation coefﬁcient (r) and statistical signiﬁ-
cance (P). Abbreviations: AVLT = Rey Auditory Verbal Learning Test; DR = delayed
recall; TL = total learning; BNT = Boston Naming Test; AVF = Animal Verbal Fluency
Test; RPM = Raven's Progressive Matrices.
Correlation between amyloid tracer retention and cognitive test scores
BDNF
met +ve
BDNF
met −ve
BDNF
met +ve
BDNF
met −ve
APOE
ε4 +ve
APOE
ε4 +ve
APOE
ε4 −ve
APOE
ε4 −ve
r P r P r P r P
AVLT DR 0.62 0.01 0.14 0.61 0.19 0.49 0.15 0.56
AVLT TL 0.58 0.02 0.18 0.51 0.12 0.65 0.02 0.95
BNT 0.18 0.49 0.03 0.91 0.06 0.81 0.07 0.78
AVF 0.04 0.88 0.21 0.44 0.11 0.69 0.42 0.09
RPM 0.36 0.17 0.00 1.00 0.03 0.92 0.10 0.72
517K. Adamczuk et al. / NeuroImage: Clinical 2 (2013) 512–520Aβ related injury. A formal pairwise comparison however of the regres-
sion slopes of β amyloid load versus episodic memory scores between
the groups did not reach signiﬁcance, possibly due to the relatively
small sample size. The relationship between cognitive test scores in
cognitively intact individuals and Aβ deposition is still a topic of active
research, with some studies reporting an inverse relationship and
others an absence of any relationship (Chételat et al., 2011; Mormino
et al., 2009; Pike et al., 2007; Rentz et al., 2010; Resnick et al., 2010).
Our ﬁndings offer one possible explanation for this divergence between
studies: if the genetic composition differs between cohorts, this may
cause differences in how β amyloid load relates to episodic memory
scores (Fig. 4 A, B). The effect of Aβ load on episodic memory scores in
the BDNFmet + ve/APOE ε4 + ve group highlights the behavioral rel-
evance of our ﬁndings.
Previous studies have shown the negative effect of BDNF codon
66 val to met substitution on a number of parameters: It is associated
with worse memory function (Chen et al., 2004; Egan et al., 2003;
Hariri et al., 2003; McAllister et al., 2012; Miyajima et al., 2008;
Voineskos et al., 2011), lower fMRI responses in hippocampi during
518 K. Adamczuk et al. / NeuroImage: Clinical 2 (2013) 512–520both encoding and retrieval (Egan et al., 2003; Hariri et al., 2003),
smaller volumes of hippocampi (Bueller et al., 2006; Hajek et al.,
2012; Miyajima et al., 2008; Pezawas et al., 2004; Szeszko et al.,
2005), lateral prefrontal cortex (Nemoto et al., 2006, Pezawas et al.,
2004, Yang et al., 2012), temporal neocortex, cingulate, and insula
(Yang et al., 2012), and amygdalae (Montag et al., 2009; Sublette
et al., 2008), as well as age-related volume reduction of other cortical
areas which may be gender-dependent (Nemoto et al., 2006). The
BDNF codon 66 met allele also affects white matter connectivity
(Chiang et al., 2009). Interestingly, a recent study reported effects of
BDNF val66met polymorphism on brain metabolism in healthy con-
trols, MCI and AD cases (Xu et al., 2010). To the best of our knowledge
our study is the ﬁrst to directly examine how the well-studied
negative effects of BDNF met relate to subclinical Aβ amyloid and its
relationship to episodic memory.
An interaction effect between BDNF and APOE on amyloid ligand
retention has not been reported in previous genome-wide association
studies (GWAS) of clinically probable Alzheimer's disease patients. In
their conventional form, GWAS make use of massively univariate
single-locus tests. Such tests are designed to search for single disease-
associated polymorphisms (Huang et al., 2007) where each gene vari-
ant is tested individually for association with a speciﬁc phenotype
(cases versus controls) (Cordell, 2009). GWAS in their classical form
will miss interaction effects between genes.
Apart from amyloid load, it is currently unknown how the inter-
action between BDNF and APOE polymorphisms affects other contrib-
utors to the pathogenesis of AD, such as synapse loss, cholinergic
depletion, or neuroﬁbrillary tangle formation. For this reason, it
remains to be seen whether the interaction effect between BDNF
and APOE on amyloid burden we observed in cognitively intact sub-
jects can be extrapolated to genetic comparisons between clinically
probable AD and controls.
Studies in animal models of AD offer us with several putative
mechanisms through which BDNF and the amyloid cascade may in-
teract. Intra-hippocampal injections of Aβ(1–42) in rats reduce the
expression of BDNF and also result in decreased BDNF levels in pre-
frontal cortex (Christensen et al., 2008). In amyloid precursor protein
(APP) double transgenic mice with both the Swedish and the Indiana
APP mutations, BDNF gene delivery to entorhinal cortex reverses
synapse loss and improves cell signaling, partially normalizes APP-
related alterations in hippocampal and entorhinal gene expression,
and restores learning and memory (Nagahara et al., 2009). In AD
postmortem samples, BDNF protein expression as well as mRNA
levels are decreased in hippocampi and other cortical areas (Connor
et al., 1997; Ferrer et al., 1999; Hock et al., 2000; Holsinger et al.,
2000; Phillips et al., 1991). During the course of AD, BDNF serum
concentration levels correlate with the severity of dementia: levels
are increased in early stages of AD and decreased in the advanced
stages (Erickson et al., 2010; Laske et al., 2006). It however is difﬁcult
to speculate on the exact mechanism through which BDNF may inter-
act with APOE to increase amyloid burden as the relationship
between APOE and increased amyloid aggregation itself is still rela-
tively poorly understood. Both genes have been implicated in neural
plasticity. This concept encompasses widely diverse processes
(Mesulam, 1999). Possibly, the efﬁcacy with which neurons dispose
of toxic forms of Aβ may depend on pathways that are linked to
lipid metabolism and neuronal survival in which APOE and BDNF,
respectively, play pivotal roles.
In conclusion, we demonstrate an association between BDNF met
allele and PET measures of amyloid deposition in cognitively normal
older adult APOE ε4 carriers. This ﬁnding provides empirical evidence
for a role of the BDNF-TrkB pathway not only in neural plasticity but
also in the pathogenesis of Alzheimer's disease (Mesulam, 1999). It
underscores the opportunity to use brain imaging measurements
to help characterize the individual and epistatic effects of putative
genetic risk factors in the predisposition to AD. We however wouldlike to emphasize that the current study is hypothesis-generating
and needs further replication.Acknowledgments
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